TRAX — First Tracks Biotherapeutics, I
Is TRAX overbought or oversold? Here is the current MarketMoodz read.
First Tracks Biotherapeutics, I (TRAX) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $43.57. The rating moved from Oversold to Strong Oversold on November 17, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$43.57
- Last changeMoved from Oversold to Strong Oversold on November 17, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
First Tracks Biotherapeutics, I (TRAX) is a small-cap biotherapeutics exposure with the typical binary-event upside and downside profile tied to clinical and dealflow catalysts. Public information and sector flows suggest limited near-term directional conviction: absent positive clinical readouts, licensing or financing news, the name is likely to trade in a range and be sensitive to funding and liquidity developments. Potential upside stems from successful trial data or partnership announcements; primary downside drivers are trial setbacks, capital raises (dilution) and competition. Current market tone—consolidation with selective support for larger, defensive pharma—reduces immediate tailwinds for speculative small-cap biotech names.
Key factors
- Company profile: Small-cap biotherapeutics exposure with typical biotech binary-event sensitivity (clinical readouts, regulatory milestones, partnerships).
- Financial health: Limited public-commercial revenue profile increases reliance on capital markets or partnerships to fund operations and programs.
- Growth catalysts: Upcoming clinical data, licensing or collaboration deals, and potential business-development interest could drive discrete upside.
- Market context: Risk-on but consolidated market tone and defensive flows into large-cap pharma reduce speculative appetite for smaller biotech names in near term.
- Sector tailwinds: Distributor/specialty pharmacy and obesity/GLP-1 thematic strength benefits related service providers and consolidators, but direct readthrough to TRAX is limited.
- Liquidity and investor base: Likely thin trading volume and concentrated ownership that can accentuate price moves on limited news.
Risks
- Clinical or regulatory failure on one or more programs producing sharp negative share-price reaction.
- Funding risk: need to raise capital through dilution or deal financing at unfavorable terms if cash runway is limited.
- Commercial execution risk and long timeline to revenue for novel therapeutics; market adoption and reimbursement uncertainty.
- Competition from larger pharma/biotech with deeper resources and established commercial channels.
- Low liquidity leading to outsized volatility and difficulty exiting positions during adverse markets.
- Macro/sector risk: rotation into defensive large-caps or weak risk appetite can reduce interest in small biotech stocks.
See today's live rating, score and targets
Members see the live hourly rating for TRAX — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.